Back to search

Article

Chemoresistance of <i>TP53</i> mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

2024-06-10

Abstract excerpt

Acute myeloid leukemia (AML) with mutations in the tumor suppressor gene, TP53 ( TP53 mut AML), is fatal with a median survival of only 6 months. RNA sequencing on purified AML patient samples show TP53 mut AML has higher expression of mevalonate pathway genes. We retrospectively identified a survival benefit in TP53 mut AML patients who received chemotherapy concurrently with a statin, which inhibits the meva...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
80f53b9f-ba4f-5f1e-871a-8460b35087ce
DOI
10.1101/2024.06.07.597976
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Chemoresistance of <i>TP53</i> mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress responseDOI 10.1101/2024.06.07.597976
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.Semantic proximity
Mitochondrial metabolism as a target for acute myeloid leukemia treatmentSemantic proximity
Imetelstat-Mediated Alterations in Fatty Acid Metabolism To Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid LeukemiaSemantic proximity
Targeting the mitochondria in acute myeloid leukemiaSemantic proximity
Mitochondrial abnormalities as a target of intervention in acute myeloid leukemiaSemantic proximity
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cellsSemantic proximity
Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolismSemantic proximity
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic ApproachesSemantic proximity
A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugsSemantic proximity
<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity
The interplay between mutant p53 and the mevalonate pathway.Semantic proximity
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.Semantic proximity
Select a neighboring publication to make it the new centre.